Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

, and timing of VITAL-1 and VITAL-2 and other clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, patents, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Susan Ferris

Investor Relations

650-266-3200


'/>"/>
SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. , Sept. 19, ... (PGDx), a provider of advanced cancer genome analysis ... a leader in discovering and developing highly selective ... the first-ever comprehensive genomic study of malignant mixed ... of the female reproductive system, also known as ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Medical, Inc., the wholly-owned operating subsidiary of Patient ... the recently released 2011-2012 U.S. News and World ... of the SurgiCount Safety-Sponge® System, a clinically proven ... common surgical errors, retained surgical sponges.  Only 17 ...
... A new policy recommendation released on 20 July by ... of serological (blood) tests to diagnose active tuberculosis (TB). ... are different to QuantiFERON, which measures responses of white ... Active tuberculosis occurs when the TB organism has overcome ...
Cached Medicine Technology:SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 2SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 2Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 3Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis 4
(Date:9/20/2014)... 20, 2014 “Motherhood is a wonderful gift ... in their latest article , “We know that you ... can—and that’s what we want to do as well.” , ... and should expect from their Family Physicians who practice obstetrics ... new motherhood. , To learn more about Community Health ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic often ... with prescription drug coverage, may now be infiltrating Medicare ... from the Department of Health and Human Services Office ... suppliers from offering side-payments to increase sales of goods ... report highlights that two recent surveys, including one by ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
(Date:9/19/2014)... 19, 2014 According to a report ... embattled blood-thinner Xarelto, named as defendants in several lawsuits ... have moved the court to dismiss those suits because ... sufficient connection with Philadelphia.* The cases include, for instance, ... 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was brought ...
(Date:9/19/2014)... (HealthDay News) -- Although there is mounting evidence ... middle-aged and older adults in the United States ... to new research. Less than one-quarter of ... by the Department of Health and Human Services, ... for promoting health and fitness and staying independent, ...
Breaking Medicine News(10 mins):Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2
... July 24 /PRNewswire-Asia/ -- Neusoft Medical Systems Co.,Ltd. (Neusoft ... announced that its newly developed Computed,Tomography(CT) system, NeuViz 16 ... and is also marked as the first of its ... was shipped to its U.S.-based customers,recently, Neusoft Medical has ...
... offer a medical heads-up, study says, , FRIDAY, July ... trauma patients could help medical personnel identify those at ... study says. , People who abuse alcohol often ... about potentially serious health needs. But even if people ...
... , , , ... ) will provide free access for the uninsured and underinsured to ... p.m. Saturday and Sunday, July 25 and 26, at the W.O. Walker ... sponsored by MedWorks and will provide 1100 medical, 300 vision and 200 ...
... 24 Dialysis Corporation of America (Nasdaq: DCAI ) ... results on Wednesday August 5, 2009, after the close of the ... with its second quarter 2009 earnings release the following morning, Thursday, ... , Those interested in participating in the August ...
... ANN ARBOR, Mich., July 24 As the economy continues ... choices about how to spend what money they have, and children -- ... bracket -- are more at risk because of it. , ... Children,s Health taken in May 2009 shows 44 percent of families, financial ...
... , , , ... DVA ), a leading provider of kidney care services for those ... dialysis facilities in Colorado have received the 2009 End Stage Renal ... granted by the Intermountain ESRD Network (Network 15), a federally mandated, ...
Cached Medicine News:Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 2Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 3Health News:Alcohol and Trauma: Blood Test Gets to the Truth 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 3Health News:Six DaVita Clinics in Colorado Receive Silver Award for Clinical Excellence 2Health News:Six DaVita Clinics in Colorado Receive Silver Award for Clinical Excellence 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: